Krystal Biotech, Inc. — Director's Dealing 2017

Sep 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2017-09-22

Reporting Person: Krishnan Krish S (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-22	Common Stock	P	100000	$10.00	Acquired	1935249	Direct
2017-09-22	Common Stock	C	112162	—	Acquired	112162	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-09-22	Series A Convertible Preferred Stock	$	C	112162	Disposed		Common Stock (112162)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1935249	Indirect

Footnotes

F1: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.

F2: Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.

F3: Directly beneficially owned by Suma M. Krishnan, the spouse of the reporting person.